JP2003528144A - 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ - Google Patents

頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ

Info

Publication number
JP2003528144A
JP2003528144A JP2001570263A JP2001570263A JP2003528144A JP 2003528144 A JP2003528144 A JP 2003528144A JP 2001570263 A JP2001570263 A JP 2001570263A JP 2001570263 A JP2001570263 A JP 2001570263A JP 2003528144 A JP2003528144 A JP 2003528144A
Authority
JP
Japan
Prior art keywords
receptor
substance
carboxy
treating
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001570263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528144A5 (https=
Inventor
バクスター，ゴードン，スミス
コールマン，ロバート，アレクサンダー
ティルフォード，ニコラス
Original Assignee
ファーマジーン ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマジーン ラボラトリーズ リミテッド filed Critical ファーマジーン ラボラトリーズ リミテッド
Publication of JP2003528144A publication Critical patent/JP2003528144A/ja
Publication of JP2003528144A5 publication Critical patent/JP2003528144A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2001570263A 2000-03-24 2000-03-24 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ Pending JP2003528144A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/001138 WO2001072302A1 (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists

Publications (2)

Publication Number Publication Date
JP2003528144A true JP2003528144A (ja) 2003-09-24
JP2003528144A5 JP2003528144A5 (https=) 2007-05-10

Family

ID=9883925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001570263A Pending JP2003528144A (ja) 2000-03-24 2000-03-24 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ

Country Status (8)

Country Link
EP (1) EP1267867B1 (https=)
JP (1) JP2003528144A (https=)
AT (1) ATE395058T1 (https=)
AU (2) AU3445100A (https=)
CA (1) CA2402099C (https=)
DE (1) DE60038902D1 (https=)
DK (1) DK1267867T3 (https=)
WO (1) WO2001072302A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519260A (ja) * 2007-02-26 2010-06-03 メルク フロスト カナダ リミテツド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059742A1 (en) * 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506894A (ja) * 1993-12-20 1997-07-08 藤沢薬品工業株式会社 ４，５−ジアリールオキサゾール誘導体
WO1998055468A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds useful as pge2 agonists and antagonists
WO2001010426A2 (en) * 1999-08-10 2001-02-15 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506894A (ja) * 1993-12-20 1997-07-08 藤沢薬品工業株式会社 ４，５−ジアリールオキサゾール誘導体
WO1998055468A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds useful as pge2 agonists and antagonists
WO2001010426A2 (en) * 1999-08-10 2001-02-15 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6010021460; Ｐｒａｄａｌｉｅｒ　Ａ．: 'ＮＳＡＩＤｓ' Ｃｅｐｈａｌａｌｇｉａ １９巻, 1999, ｐｐ．１９９-２００ *
JPN6010021461; Ｃｏｌｅｍａｎ　Ｒ．Ａ．　ｅｔ　ａｌ．: 'Ａ　ｎｏｖｅｌ　ｉｎｈｉｂｉｔｏｒｙ　ｐｒｏｓｔａｎｏｉｄ　ｒｅｃｅｐｔｏｒ　ｉｎ　ｐｉｇｌｅｔ　ｓａｐｈｅｎｏｕｓ　ｖｅｉｎ' Ｐｒｏｓｔａｇｌａｎｄｉｎｓ ４７巻, 1994, ｐｐ．１５１-１６８ *
JPN6010021463; Ｍａｒｉｎ　Ｐ．Ａ．: 'Ｐｈａｒｍａｃｏｌｏｇｙ　Ｕｐｄａｔｅ：Ｐｈａｒｍａｃｏｌｏｇｉｃ　Ｍａｎａｇｅｍｅｎｔ　ｏｆ　Ｍｉｇｒａｉｎｅ' Ｊｏｕｒｎａｌ　ｏｆ　ｔｈｅ　Ａｍｅｒｉｃａｎ　Ａｃａｄｅｍｙ　ｏｆ　Ｎｕｒｓｅ　Ｐｒａｃｔｉｔｉｏｎｅｒｓ １０巻９号, 199809, ｐｐ．４０７-４１２ *
JPN6010021468; Ｂｈａｔｔａｃｈａｒｙａ　Ｍ．　ｅｔ　ａｌ．: 'Ｌｏｃａｌｉｚａｔｉｏｎ　ｏｆ　Ｆｕｎｃｔｉｏｎａｌ　Ｐｒｏｓｔａｇｌａｎｄｉｎ　Ｅ２　Ｒｅｃｅｐｔｏｒｓ　ＥＰ３　ａｎｄ　ＥＰ４　ｉｎ　ｔｈｅ　Ｎｕｃｌｅａｒ　Ｅｎｖｅｌｏｐｅ' Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｌｏｇｉｃａｌ　Ｃｈｅｍｉｓｔｒｙ ２７４巻２２号, 1999, ｐｐ．１５７１９-１５７２４ *
JPN6013046174; Ａｎｄｒｅｗ　Ａ　Ｐａｒｓｏｎｓ　ｅｔ　ａｌ: 'Ｅｆｆｅｃｔｓ　ｏｆ　ｐｒｏｓｔａｎｏｉｄｓ　ｏｎ　ｈｕｍａｎ　ａｎｄ　ｒａｂｂｉｔ　ｂａｓｉｌａｒ　ａｒｔｅｒｉｅｓ　ｐｒｅｃｏｎｔｒａｃｔｅｄ　ｉｎ　ｖｉｔｒｏ' Ｃｅｐｈａｌａｌｇｉａ ｖｏｌ．　９，　ｎｏ．　３, 1989, ｐｐ．　１６５-１７２

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519260A (ja) * 2007-02-26 2010-06-03 メルク フロスト カナダ リミテツド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体

Also Published As

Publication number Publication date
CA2402099A1 (en) 2001-10-04
DE60038902D1 (de) 2008-06-26
WO2001072302A1 (en) 2001-10-04
ATE395058T1 (de) 2008-05-15
CA2402099C (en) 2011-04-26
EP1267867A1 (en) 2003-01-02
AU3445100A (en) 2001-10-08
EP1267867B1 (en) 2008-05-14
AU2000234451B2 (en) 2005-09-29
DK1267867T3 (da) 2008-08-25

Similar Documents

Publication Publication Date Title
US8552040B2 (en) Isoxazoline compounds having MIF antagonist activity
US8513027B2 (en) Method of identifying an inhibitor of the prostanoid EP4 receptor
KR20010032304A (ko) 알도스 환원효소 억제제 및 글리코겐 포스포릴라제억제제의 혼합물
JP2003528144A (ja) 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ
Mazaleuskaya et al. Druggable prostanoid pathway
AU2000234451A1 (en) Use of prostanoid EP4 receptor antagonists for the treatment of headache and assays for such antagonists
JP2004510705A (ja) 方法
JP2000503298A (ja) メデトミジン誘導体のレボエナンチオマーの医薬組成物および使用
EP1047413B1 (fr) Composition pharmaceutique comprenant un inhibiteur spécifique de l'aminopeptidase a, en particulier l'ec33, pour diminuer la pression artérielle
JP2002527357A (ja) イミダゾリン受容体結合性化合物
US7109245B2 (en) Vasoconstrictor cannabinoid analogs
US7199126B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20030158240A1 (en) Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment
Pace-Asciak et al. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition
MXPA04011282A (es) Uso de valsartan o su metabolito para inhibir agregacion de plaqueta.
JP4512052B2 (ja) Ｐｄｅ７インヒビターの新規用途
US6221860B1 (en) Beta-lactam inhibitors of CoA-IT
Kuo et al. NP‐313, 2‐acetylamino‐3‐chloro‐1, 4‐naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A2 synthesis and calcium entry
WO2004030674A1 (ja) プロスタグランジンｄ２、プロスタグランジンｄ２アゴニストおよびプロスタグランジンｄ２アンタゴニストの新規用途
JP2021534141A (ja) アルコール使用障害の治療剤
US20070173493A1 (en) 1-Oxadibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
US20070129330A1 (en) 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
JP2010047583A (ja) 原発性頭痛障害の治療のためのプロスタノイドアンタゴニストの使用
Potenza et al. Endothelial cyclo-oxygenase-1 and-2 differentially affect reactivity of mesenteric vascular bed in portal hypertensive rats

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100715

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308